Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$86.84 USD

86.84
2,372,511

+0.64 (0.74%)

Updated Oct 11, 2024 02:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

AtriCure Gets CE Mark for EnCompass Clamp, Expands in Europe

ATRC's EnCompass Clamp receives a CE Mark, enabling European surgeons to access faster, simpler heart ablation in cardiac surgeries with advanced radiofrequency technology.

Boston Scientific (BSX) Falls More Steeply Than Broader Market: What Investors Need to Know

Boston Scientific (BSX) reachead $86.20 at the closing of the latest trading day, reflecting a -0.58% change compared to its last close.

InspireMD Gains FDA Premarket Approval for CGuard Prime Carotid Stent

NSPR gains premarket approval for its CGuard Prime carotid stent system for use in United States for treating carotid artery stenosis.

CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica

Charles River and Lundbeck sign an agreement to use Logica to advance the discovery of novel neurological drugs.

Urmimala Biswas headshot

MDT Stock Trades Near 52-Week High: Is it a Smart Buy Now?

The latest rate cut should help Medtronic expand in the AFib, structural heart, robotics, neuromodulation, hypertension and diabetes markets.

CAH Stock May Gain Following the Distribution Deal With T2 Biosystems

Cardinal Health and T2 Biosystems announce an agreement selecting the former to sell direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens.

Integer Holdings (ITGR) Gains 30.5% YTD: What's Driving the Stock?

Integer Holdings (ITGR) shares gain on the back of growth in the Medical segment. However, fluctuations in raw material prices and the oil and energy market are concerning.

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?

Here is how Boston Scientific (BSX) and Arcellx, Inc. (ACLX) have performed compared to their sector so far this year.

Should You Add Quest Diagnostics Stock to Your Portfolio Right Now?

DGX's strength in Advanced Diagnostics and robust base business volumes are encouraging.

Robust Plasma Sales, New Innovations Aid Haemonetics Stock

HAE's hospital portfolio is evolving and helping to create new opportunities for growth and diversification.

AMN Stock Down Despite WorkWise Launch to Enhance Healthcare Delivery

AMN Healthcare aims to enhance staffing efficiency and improve operational efficiency in healthcare systems via the latest launch.

PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer

PROCEPT BioRobotics receives FDA's approval to begin a pivotal randomized clinical study to assess the use of Aquablation therapy in treating prostate cancer patients.

Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now

QDEL's strong product portfolio raises optimism about the stock.

TMO's New ICP-MS Systems Boost Trace Element Analysis: Stock to Gain?

Thermo Fisher introduces the iCAP MX Series ICP-MS to simplify trace elemental analysis.

Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy?

Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Zacks.com featured highlights include Royal Caribbean Cruises, Boston Scientific and Monolithic Power Systems

Royal Caribbean Cruises, Boston Scientific and Monolithic Power Systems have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

3 Profitable S&P 500 Stocks for the Best Quarter of the Year

Royal Caribbean Cruises, Boston Scientific and Monolithic Power Systems have been selected as the top picks with a high net income ratio.

Boston Scientific (BSX) Rises Yet Lags Behind Market: Some Facts Worth Knowing

In the most recent trading session, Boston Scientific (BSX) closed at $84.54, indicating a +0.86% shift from the previous trading day.

Reasons to Add Baxter International Stock to Your Portfolio Now

BAX's robust growth across all regions, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Three Reasons Why You Should Hold BDX Stock in Your Portfolio Now

BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns.

ACB Stock Likely to Gain From Genome BC-Funded Aroma Research Project

Aurora Cannabis' new collaboration on the Genome BC-Funded Project addresses distinct cannabis aromas.

Why Boston Scientific (BSX) Outpaced the Stock Market Today

Boston Scientific (BSX) closed at $84.49 in the latest trading session, marking a +0.42% move from the prior day.

SRDX Stock Down Despite FDA Clearance for Pounce XL System

Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market.

Here's Why You Should Add BSX Stock to Your Portfolio Now

Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive MedSurg market share gain.

Reasons to Retain DexCom Stock in Your Portfolio for Now

DXCM continues to raise optimism among investors, owing to its strong product portfolio.